What is HC Wainwright's Estimate for DAWN Q1 Earnings?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Investment analysts at HC Wainwright dropped their Q1 2025 EPS estimates for shares of Day One Biopharmaceuticals in a report released on Thursday, April 3rd. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.37) per share for the quarter, down from their prior estimate of ($0.28). HC Wainwright has a "Buy" rating and a $36.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals' Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($1.12) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at $0.75 EPS, FY2028 earnings at $0.84 EPS and FY2029 earnings at $1.35 EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The company had revenue of $29.21 million for the quarter, compared to analyst estimates of $27.11 million.

Other equities research analysts have also issued reports about the company. Needham & Company LLC reissued a "buy" rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Bank of America lowered their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. Wedbush restated an "outperform" rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. The Goldman Sachs Group reduced their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a research report on Tuesday, March 25th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating on the stock in a research report on Wednesday, March 5th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $32.29.

Remove Ads

Day One Biopharmaceuticals Stock Performance

Shares of Day One Biopharmaceuticals stock traded up $0.36 on Monday, hitting $7.12. The company had a trading volume of 1,297,624 shares, compared to its average volume of 1,117,362. Day One Biopharmaceuticals has a 1 year low of $6.41 and a 1 year high of $18.07. The stock has a 50 day moving average of $9.33 and a 200-day moving average of $12.05. The stock has a market capitalization of $721.65 million, a price-to-earnings ratio of -6.91 and a beta of -1.24.

Insiders Place Their Bets

In other news, CFO Charles N. York II sold 4,370 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $52,265.20. Following the completion of the sale, the chief financial officer now owns 252,638 shares in the company, valued at $3,021,550.48. This trade represents a 1.70 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jeremy Bender sold 12,048 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $144,094.08. Following the completion of the transaction, the chief executive officer now owns 128,015 shares in the company, valued at approximately $1,531,059.40. The trade was a 8.60 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,064 shares of company stock valued at $251,925. Company insiders own 8.40% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC lifted its holdings in Day One Biopharmaceuticals by 73.9% during the fourth quarter. FMR LLC now owns 12,887,467 shares of the company's stock valued at $163,284,000 after purchasing an additional 5,475,087 shares during the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of Day One Biopharmaceuticals in the fourth quarter valued at approximately $31,829,000. Boxer Capital Management LLC purchased a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at approximately $15,077,000. Marshall Wace LLP bought a new position in Day One Biopharmaceuticals in the 4th quarter worth approximately $13,909,000. Finally, Estuary Capital Management LP grew its stake in Day One Biopharmaceuticals by 35.5% in the 4th quarter. Estuary Capital Management LP now owns 3,716,777 shares of the company's stock valued at $47,092,000 after buying an additional 972,997 shares in the last quarter. Institutional investors own 87.95% of the company's stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.